Alector, Inc. (ALEC, Financial) experienced a notable increase in its stock price by 5.09%. The shares are currently priced at $4.75, with a trading volume of 162,647 shares, a turnover rate of 0.17%, and a volatility of 5.53%.
Recent financial reports show Alector achieved revenue of $15.08 million, a net loss of $38.68 million, with earnings per share at -$0.40 and gross profit at $12.80 million. The company's price-to-earnings ratio stands at -2.62. Regarding institutional ratings, 73% of brokers recommend buying, 18% suggest holding, and 9% advise selling the stock.
In the biotech industry, where Alector operates, the overall increase is 0.12%. Notably, related stocks such as Nkgen Biotech Inc, Portage Biotech Inc., and Bio-Path Holdings, Inc. have shown significant gains. Other active stocks include Aditxt, Inc., Bio-Path Holdings, Inc., and Gri Bio, Inc., with turnover rates of 2491.20%, 2380.16%, and 255.81%, respectively. Stocks with high volatility include Nkgen Biotech Inc, Virios Therapeutics, Inc., and Bio-Path Holdings, Inc., with respective fluctuations of 66.06%, 46.27%, and 45.80%.
Alector Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurodegenerative diseases. Their therapeutic approach aims to restore brain health by enhancing immune functions, with pipeline products, including AL001, AL002, AL003, and AL101.
